Literature DB >> 10550186

Neovascularization during venous thrombosis organization: a preliminary study.

T W Wakefield1, M J Linn, P K Henke, A M Kadell, C A Wilke, S K Wrobleski, M Sarkar, M D Burdick, D D Myers, R M Strieter.   

Abstract

PURPOSE: Thrombus organization after venous thromboembolism leading to recanalization occurs at a variable rate. The angiogenic chemokine interleukin-8 (IL-8) has been found in thrombus months after thrombus initiation. We hypothesize that thrombus organization involves neovascularization and leukocyte influx and that IL-8 administered at thrombus induction will promote thrombus organization.
METHODS: A group of rats underwent inferior vena caval occlusive thrombosis. At thrombus induction and every 24 hours, the rats were administered IL-8 (1 microgram) or serum albumin. The rats were killed at either day 4, day 8, or day 12, and, at death, colloidal carbon was perfused via the heart. The inferior vena cava was isolated, measured, weighed, and formalin fixed. The sections were stained with anti-polymorphonuclear leukocyte antibody, the endothelial marker factor VIII-related antigen, and with hematoxylin and eosin. Thrombus neovascularization (colloidal carbon) with morphometric analysis was normalized to the total thrombus area. In addition, the rats underwent perfusion with fluorescein isothiocyanate dextran (molecular weight, 150,000) at death to correlate with colloidal carbon perfusion, and thrombus fluorescence was determined.
RESULTS: Thrombus cellularity initially involved neutrophils, followed by monocytes. Significantly more neutrophils, monocytes, and cells that were defined as spindle shaped (fibroblasts and endothelial cells) were noted in the animals treated with IL-8. Neovascularization was significantly increased at day 4 in the animals treated with IL-8 versus the animals treated with serum albumin and was corroborated with a significant increase in thrombus fluorescein isothiocyanate dextran fluorescence at day 4 in the rats treated with IL-8. Colloidal carbon perfusion was noted within vascular channels without extravasation and colocalized with factor VIII-related antigen.
CONCLUSION: This study shows that thrombus organization involves neovascularization and that IL-8 augments thrombus organization.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10550186     DOI: 10.1016/s0741-5214(99)70013-3

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  18 in total

1.  Absence of IFN-γ accelerates thrombus resolution through enhanced MMP-9 and VEGF expression in mice.

Authors:  Mizuho Nosaka; Yuko Ishida; Akihiko Kimura; Yumi Kuninaka; Masanori Inui; Naofumi Mukaida; Toshikazu Kondo
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

2.  Endovascular Treatment with Platinum Coils. Recanalization is Associated with Early Increased von Willebrand Factor mRNA.

Authors:  J Raymond; C Ogoudikpe; A Metcalfe; I Salazkin; G Gevry; O Robledo
Journal:  Interv Neuroradiol       Date:  2006-07-31       Impact factor: 1.610

3.  Endothelial progenitor cells overexpressing platelet derived growth factor-D facilitate deep vein thrombosis resolution.

Authors:  Haolong Zhang; Hailong Luo; Bo Tang; Yikuan Chen; Jian Fu; Jianming Sun
Journal:  J Thromb Thrombolysis       Date:  2021-10-20       Impact factor: 2.300

4.  NF-kappaB transcription factor p50 critically regulates tissue factor in deep vein thrombosis.

Authors:  Yi-Dan Li; Bu-Qing Ye; Sheng-Xi Zheng; Jin-Tao Wang; Jian-Guo Wang; Ming Chen; Ji-Guo Liu; Xin-Hui Pei; Li-Jing Wang; Zhi-Xin Lin; Kalpna Gupta; Nigel Mackman; Arne Slungaard; Nigel S Key; Jian-Guo Geng
Journal:  J Biol Chem       Date:  2008-12-18       Impact factor: 5.157

5.  Recanalization and flow regulate venous thrombus resolution and matrix metalloproteinase expression in vivo.

Authors:  Christine Chabasse; Suzanne A Siefert; Mohammed Chaudry; Mark H Hoofnagle; Brajesh K Lal; Rajabrata Sarkar
Journal:  J Vasc Surg Venous Lymphat Disord       Date:  2014-05-10

6.  Natural history of experimental arterial chronic total occlusions.

Authors:  Ronen Jaffe; General Leung; Nigel R Munce; Amandeep S Thind; Howard Leong-Poi; Kevan J T Anderson; Xiuling Qi; Judy Trogadis; Ariella Nadler; Davida Shiff; Jamie Saperia; Julia Lockwood; Chaim Jacobs; Beiping Qiang; Aaron Teitelbaum; Alexander J Dick; John D Sparkes; Jagdish Butany; Graham A Wright; Bradley H Strauss
Journal:  J Am Coll Cardiol       Date:  2009-03-31       Impact factor: 24.094

7.  18F-fluorodeoxyglucose positron emission tomography/computed tomography enables the detection of recurrent same-site deep vein thrombosis by illuminating recently formed, neutrophil-rich thrombus.

Authors:  Tetsuya Hara; Jessica Truelove; Ahmed Tawakol; Gregory R Wojtkiewicz; William J Hucker; Megan H MacNabb; Anna-Liisa Brownell; Kimmo Jokivarsi; Chase W Kessinger; Michael R Jaff; Peter K Henke; Ralph Weissleder; Farouc A Jaffer
Journal:  Circulation       Date:  2014-07-28       Impact factor: 29.690

8.  Time-dependent appearance of intrathrombus neutrophils and macrophages in a stasis-induced deep vein thrombosis model and its application to thrombus age determination.

Authors:  Mizuho Nosaka; Yuko Ishida; Akihiko Kimura; Toshikazu Kondo
Journal:  Int J Legal Med       Date:  2009-02-05       Impact factor: 2.686

9.  Angiostatic factors in the pulmonary endarterectomy material from chronic thromboembolic pulmonary hypertension patients cause endothelial dysfunction.

Authors:  Diana Zabini; Chandran Nagaraj; Elvira Stacher; Irene M Lang; Patrick Nierlich; Walter Klepetko; Akos Heinemann; Horst Olschewski; Zoltán Bálint; Andrea Olschewski
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

10.  Potent platelet inhibition with peri-procedural tirofiban may attenuate progression of atherosclerosis in patients with acute coronary syndromes.

Authors:  Akihiro Nakajima; Makoto Araki; Osamu Kurihara; Hang Lee; Sunao Nakamura; Ik-Kyung Jang
Journal:  J Thromb Thrombolysis       Date:  2021-07-17       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.